title: Does surgical resection of pulmonary metastases of head and neck cancer improve survival?
abstract: BACKGROUND
  The prognosis of patients with metastasized head and neck cancer is poor. Limited experience exists with the benefit of resection of lung metastases and systematic mediastinal and hilar lymph node dissection on survival of patients with head and neck carcinoma.
  
  
  METHODS
  Eighty patients undergoing metastasectomy for pulmonary metastases of primary head and neck cancer entered the study. Multivariate analysis was performed by Cox regression analysis. Survival differences between patients operated and those not operated on were analyzed by matched pair analysis.
  
  
  RESULTS
  From 1984 until 2006, pulmonary metastases were diagnosed in 332 patients treated for head and neck cancer; 80 of these were admitted to our department for resection. Metastases of the primary head and neck tumor were confirmed histologically in 67 patients. The median overall survival after resection of lung metastases was 19.4 months and was statistically significantly better compared with patients who were not operated on (P < .001). The multivariate analysis after metastasectomy revealed that incomplete resection of pulmonary lesions, complications associated with surgery, and adjuvant therapy of the primary tumor are independent negative prognostic factors for survival. We observed a trend to improved survival in patients without hilar or mediastinal lymph node metastases.
  
  
  CONCLUSIONS
  The survival rate of patients operated on was statistically significantly higher than that of patients with conservative treatment. Even patients with multiple or bilateral pulmonary lesions after curative treatment of a primary tumor should be operated on if there is no contraindication against an extended surgical procedure and a complete resection of the metastases seems achievable.
authors.affiliation: Department of Surgery, University of Munich, Grosshadern Campus, Marchioninistrasse 15, Munich, 81377, Germany. hwinter@med.uni-muenchen.de
authors.forename: Hauke
authors.initials: H
authors.lastname: Winter
authors.forename: Georgios
authors.initials: G
authors.lastname: Meimarakis
authors.forename: Gabriele
authors.initials: G
authors.lastname: Hoffmann
authors.forename: Manuela
authors.initials: M
authors.lastname: Hummel
authors.forename: Dominik
authors.initials: D
authors.lastname: Rüttinger
authors.forename: Astrid
authors.initials: A
authors.lastname: Zilbauer
authors.forename: Klaus
authors.initials: K
authors.lastname: Stelter
authors.forename: Fritz
authors.initials: F
authors.lastname: Spelsberg
authors.forename: Karl-Walter
authors.initials: KW
authors.lastname: Jauch
authors.forename: Rudolph
authors.initials: R
authors.lastname: Hatz
authors.forename: Florian
authors.initials: F
authors.lastname: Löhe
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000556:secondary / Q000601:surgery; D005260:Female; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome